Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia

Bioconjugate Chemistry

Volumn 18, Issue 3, 2007, Pages 912-921

  Hok, Saphon ^a   Natarajan, Arutselvan ^b   Balhorn, Rod ^a   DeNardo, Sally J ^b   DeNardo, Gerald L ^b   Perkins, Julie ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; CHELATION; CHLORINE COMPOUNDS; DISEASES; LIGANDS; MAMMALS; ONCOLOGY;

B CELLS; CELL SURFACE RECEPTORS; CHLORIDE RESIN; HIGH AFFINITY LIGANDS; MOLECULAR TARGETING; NON-HODGKIN LYMPHOMA; POLYMER SUPPORTED SYNTHESIS; RADIOLABELLING; SOLID POLYMERS; SYNTHESISED;

ANTIBODIES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CELL SURFACE RECEPTOR; COBALT 60; COBALT CHLORIDE; EPITOPE; HLA DR ANTIGEN; HLA DR10 ANTIGEN; INDIUM 111; LIGAND; MONOCLONAL ANTIBODY LYM 1; POLYMER; RADIOISOTOPE; RESIN; TRITYL DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BETA SHEET; BINDING AFFINITY; CHELATION; CONJUGATION; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA; MOLECULAR WEIGHT; NONHODGKIN LYMPHOMA; QUANTUM YIELD; RADIOCHEMISTRY; RECEPTOR UPREGULATION;

MUS;

EID: 34347353345     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060305o     Document Type: Article

References (34)

1. Carter, P. J. (2006) Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357.
2. Presta, L. G. (2005) Selection, design and engineering of therapeutic antibodies. J. Allergy Clin. Immunol. 116, 731-736.
3. Rose, L. M., Gunasekera, A. H., DeNardo, S. J., DeNardo, G. L., and Meares, C. F. (1996) Lymphoma selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol. Immunother. 43, 26-30.
4. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., and Taylor, C. R. (1987) 2 new monoclonal-antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res. 47, 830-840.
5. Rose, L. M., Deng, C. T., Scott, S. L., Xiong, C. Y., Lamborn, K. R., Gumerlock, P. H., DeNardo, G. L., and Meares, C. F. (1999) Critical Lym-1 binding residues on polymorphic HLA-DR10 molecules. Mol. Immunol. 36, 789-787.
6. Cheson, B. D. (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101, 391-398.
7. DeNardo, G. L., O'Donnell, R. T., Oldham, R. K., and DeNardo, S. J. (1998) A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother. Radiopharm. 13, 213-223.
8. DeNardo, G. L. (2005) Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin. Nucl. Med. 35, 202-211.
9. Juweid, M. E. (2002) Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice. J. Nucl Med. 43, 1507-1529.
10. DeNardo, G. L., DeNardo, S. J., Goldstein, D. S., Kroger, L. A., Lambom, K. R., Levy, N. B., McGahan, J. P., Salako, Q., Shen, S., and Lewis, J. P. (1998) Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol. 16, 3246-3256.
11. Goldenberg, D. M. (2001) The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hemat. 39, 195-201.
12. Cutler, C. S., Smith, C. J., Ehrhardt, G. J., Tyler, T. T., Jurisson, S. S., and Deutsch, E. (2000) Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother. Radiopharm. 15, 531-545.
13. Imai, K., and Takoaka, A. (2006) Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714-727.
14. Shuker, S. B., Hajduk, P. J., Meadows, R. P., and Fesik, S. W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534.
15. Kramer, R. H., and Karpen, J. W. (1998) Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature (London) 395, 710-713.
16. Maly, D. J., Choong, I. C., and Ellman, J. A. (2000) Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. U.S.A. 97, 2419-2424.
17. Kitov, P. I., Sadowska, J. M., Mulvey, G., Armstrong, G. D., Ling, H., Pannu, N. S., Read, R. J., and Bundle, D. R. (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature (London) 403, 669-672.
18. Fan, E. K., Zhang, Z. S., Minke, W. E., Hou, Z., Verlinde, C., and Hoi, W. G. J. (2000) High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design. J. Am. Chem. Soc. 122, 2663-2664.
19. Mammen, M., Choi, S. K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. Engl. 37, 2755-2794.
20. Albrecht, H., Cosman, M., Ngu-Schwemlein, M., Corzett, M., Curran, K. W., Hok, S., Dolan, C., Fang, X., DeNardo, S. J., DeNardo, G. L., and Balhom, R. Recombinant HLA-DR10 beta-subunit for developing novel targeting agents for non-Hodgkin's lymphoma. Submitted.
21. Balhom, R., Hok, S., Burke, P. A., Lightston, F. C., Cosman, M., Zemla, A., Mirick, G., Perkins, J., Natarajan, A., Corzett, M., DeNardo, S. J., Lehner, T. A., Albrecht, H., Gregg, J. P., and DeNardo, G. L. (2007) Selective high affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/ leukemia. Clin. Cancer Res., in press.
22. Charton, J., Gassiot, A. C., Girault-Mizzi, S., Debreu-Fontaine, M. A., Melnyk, P., and Sergheraert, C. (2005) Synthesis and pharmacological evaluation of Tic-hydantoin derivatives as selective sigma(1) ligands. Part 1. Bioorg. Med. Chem. Lett. 15, 4833-4837.
23. Barlos, K., Gatos, D., Kallitsis, J., Papaphotiu, G., Sotiriu, P., Yao, W. Q., and Schafer, W. (1989) Synthesis of protected peptide-fragments using substituted triphenylmethyl resins. Tetrahedron Lett. 30, 3943-3946.
24. Barlos, K., Gatos, D., Kapolos, S., Papaphotiu, G., Schafer, W., and Yao, W. Q. (1989) Esterification of partially protected peptide-fragments with resins - Utilization of 2-chlorotritylchloride for synthesis of leu-15-gastrin-I. Tetrahedron Lett. 30, 3947-3950.
25. Chan, W. C., and White, P. D. (2000) Fmoc solid phase peptide synthesis. A practical approach. Oxford University Press, Oxford.
26. Kates, S. A., Sole, N. A., Beyermann, M., Barany, G., and Albericio, F. (1996) Optimized preparation of deca(L-alanyl)-L-valinamide by 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase synthesis on polyethylene glycol-polystyrene (PEG-PS) graft supports, with 1,8-diazobicyclo[5.4.0]-undec- 7-ene (DBU) deprotection. Pept. Res. 9, 106-113.
27. Carpino, L. A. (1993) 1-Hydroxy-7-azabenzotriazole - an efficient peptide coupling additive. J. Am. Chem. Soc. 115, 4397-4398.
28. Diaz-Mochon, J. J., Bialy, L., and Bradley, M. (2004) Full orthogonality between Dde and Fmoc: The direct synthesis of PNA-peptide conjugates. Org. Lett. 6, 1127-1129.
29. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue, M. (1984) Conjugation of antibodies with bifunctional chelating-agents - Isothiocyanate and bromo-acetamide reagents, methods of analysis, and subsequent addition of metal-Ions. Anal. Biochem. 142, 68-78.
30. Goodwin, D. A., Meares, C. F., Watanabe, N., McTigue, M., Chaovapong, W., Ransone, C. M., Renn, O., Greiner, D. P., Kukis, D. L., and Kronenberger, S. I. (1994) Pharmacokinetics of pretargeted monoclonal-antibody 2d12.5 and Y-88 Janus-2-(P-Nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (Dota) in balb/C Mice with Khjj mouse adenocarcinoma - a model for Y-90 radioimmunotherapy. Cancer Res. 54, 5937-5946.
31. Kukis, D. L., Denardo, G. L., Denardo, S. J., Mirick, G. R., Miers, L. A., Greiner, D. P., and Meares, C. F. (1995) Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2it-bat-Lym-1 immunoconjugates. Cancer Res. 55, 878-884.
32. Ewing, T. J. A., and Kuntz, I. D. (1997) Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem. 18, 1175-1189.
33. Cosman, M., Lightstone, F. C., Krishnan, V. V., Zeller, L., Prieto, M. C., Roe, D. C., and Balhorn, R. (2002) Identification of novel small molecules that bind to two different sites on the surface of tetanus toxin C fragment. Chem. Res. Toxicol. 15, 1218-1228.
34. DeNardo, G. L., O'Donnell, R. T., Rose, L. M., Mirick, G. R., Kroger, L. A., and DeNardo, S. J. (1999) Milestones in the development of Lym-1 therapy. Hybridoma 18, 1-11.